Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report

Xuzhao Zhang, PhD, MDa,b,*, Yun Liang, PhD, MDa, Xian Li, MDa, Weiqin Wang, PhD, MDa, Jiefeng Tong, MDa, Yang Xu, PhD, MDa

Abstract

Rationale: Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV.

Patient concerns: A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs.

Diagnoses: The diagnosis was MM with chronic carrier of HBV.

Interventions: He received bortezomib-based regimen for MM as well as entecavir as a prophylaxis to prevent HBV reactivation.

Outcomes: This patient achieved HBsAg and HBV-DNA clearance after 2 months and the remission was maintained during the next 2 years. He also achieved complete remission of MM and underwent consolidation therapy with autologous hematopoietic stem cell transplantation.

Lessons: This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug. Research on related mechanisms might provide new suggestions and hope for better management of HBV positive patients with MM and for the treatment of HBV patients.

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, CR = complete response, FISH = fluorescence in situ hybridization, GWAS = genome-wide association studies, HBV = hepatitis virus B, IgG = immunoglobulin G, IGH = immunoglobulin heavy chain, ISS = International Staging System, sCR = stringent complete response.

Keywords: bortezomib, entecavir, familial multiple myeloma, HBV clearance

1. Introduction

In East Asia, chronic hepatitis B virus (HBV) infection is often seen in patients with malignancies including multiple myeloma.1–3 There is a risk of reactivation of HBV during the treatment of various tumors including multiple myeloma.4,5 With the emergence of new drugs, the treatment of multiple myeloma has now entered the era of targeted therapy from the era of traditional chemotherapy. It has been reported that treatments based on new drugs including bortezomib can also lead to reactivation of HBV.6–10 However, some studies reported that...
mg/kg of bortezomib could decrease the copies of HBV in transgenic mice in vivo,[11] although clinical evidence about the same in humans is still lacking. We report here the case of an HBV-positive patient with familial multiple myeloma, who achieved HBV clearance after treatment with a bortezomib-based regimen combined with anti-HBV drug. To our knowledge, this is the first case of HBV clearance after treatment with a bortezomib-based regimen combined with anti-HBV drug in patient with multiple myeloma.

2. Case report

A 55-year-old man was diagnosed with “lumbar muscle strain” at a local hospital after complains of low back pain for 3 months. However, no significant improvement was seen after symptomatic treatment (specific treatment unknown). Two months later, the patient developed back pain with bilateral pain in the rib area. On April 21, 2018, enhanced chest computed tomography (CT) showed a small amount of chronic inflammatory and fibroproliferative lesions in the lower lobe of both lungs; a small amount of effusion on both sides of the thoracic cavity, osteoporosis of the vertebrae, ribs, and sternum with multiple bone resorption and destruction, consider plasmacytoma possible. Blood biochemical tests suggest elevated globulin (88.2 g/L).

When the patient visited our hospital, there were no obvious positive findings on physical examination, except for pale lips, conjunctiva, and nail bed. Laboratory findings were as follows: white blood cell count, 3,400 cells/μL; hemoglobin, 86 g/L; platelets, 118,000 cells/μL; total protein, 113 g/L; albumin, 28 g/L; creatinine, 58 μmol/L; calcium, 2.24 mmol/L; β2-microglobulin, 2.84 mg/L. Immunoglobulin G (IgG) was 66.79 g/L, but IgA and IgM were below normal levels, blood lambda light chain was 19.8 g/L, and the ratio of kappa/lambda was 0.01. Immunofixation electrophoresis showed an increase in monoclonal IgG and lambda in the blood. Bone marrow smear suggested elevated plasma cells (plasma cells 23%). Fluorescence in situ hybridization (FISH) results of CD138 monoclonal antibody sorting cells showed 8% positive for immunoglobulin heavy chain (IGH) rearrangement and 10% positive for 13q deletion. The diagnosis was multiple myeloma [subtype IgG/lambda Durie-Salmon stage IIIA, International Staging System (ISS) stage II]. This patient was a known carrier of HBV for more than 20 years. His elder brother had also been diagnosed with multiple myeloma (subtype IgG/kappa) in 2008 at the age of 56 years. Before initiation of treatment for multiple myeloma, the patient was seropositive for HBsAg (391 U/mL), anti-HBe, and anti-HBc. Alamine aminotransferase (ALT) was 64 U/L (normal range <45 U/L) and aspartate aminotransferase (AST) was 69 U/L (normal range <50 U/L). Serum HBV-DNA was 161 IU/mL.

The patient received a 3-week cycle of PCD (Bortezomib 2.3 mg and Cyclophosphamide 0.4 g on day 1, 4, 8, 11+ Dexamethasone 20 mg on day 1–2, 4–5, 8–9, 11–12). Entecavir was administered as a prophylaxis against HBV reactivation, and HBV-DNA was monitored since the start of PCD therapy. The patient tolerated the chemotherapy regimen well, and there were no obvious adverse effects. After 1 cycle of therapy, the serum HBV-DNA was undetectable. HBsAg turned negative after 2 months and was also negative during the 2 years of follow-up. However, anti-HBe and anti-HBc were still positive. After 4 courses of PCD therapy, the patient’s immunofixation electrophoresis turned negative, and the free light chain returned to normal, indicating a stringent complete response (sCR).

Subsequently, his peripheral blood hematopoietic stem cells (HSCs) were collected and he was consistently treated with high-dose chemotherapy followed by autologous HSC transplantation as consolidation treatment, 10 months after the initial diagnosis of multiple myeloma. The patient continues to remain in sCR at 26 months of follow-up. During subsequent treatment and follow-up, HBsAg continued to be negative and HBV-DNA continued to fall below the detection limit.

3. Discussion

Bortezomib is a proteasome inhibitor that is currently used in the treatment of multiple myeloma, mantle cell lymphoma, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, and other plasma cell-related diseases. The rate of reactivation of the herpes zoster virus was significantly higher in patients receiving bortezomib,[12] suggesting that bortezomib might cause reactivation of the virus. In East Asian countries including China, the proportion of multiple myeloma patients who are positive for HBV infection ranges from 3.4% to 19.4%.[1,2,13] In recent years, HBV reactivation has been reported in HBV-positive patients of multiple myeloma, after receiving bortezomib-based regimens.[6–10] However, bortezomib-based regimens usually contain glucocorticoid, which has a negative effect on HBV infection,[14] and maintenance therapy with prednisolone can also result in HBV reactivation in patients of multiple myeloma.[15] Moreover, studies have shown that autologous HSC transplantation is one of the important risk factors for HBV reactivation.[16,17] These factors also influence the assessment of the role of bortezomib in HBV reactivation. More recently, a study by Hou et al[18] revealed that bortezomib might promote HBV activation by inhibiting ubiquitination degradation of HBV polymerase. However, proteasome inhibitor was reported to inhibit HBV production in vitro,[19] and in vivo. Studies conducted on transgenic mouse model have found that bortezomib can inhibit HBV replication.[11] However, there is still no clinical evidence to prove that bortezomib can inhibit HBV.

This case is unique in 2 ways: first, the patient and his elder brother were diagnosed with multiple myeloma at a similar age; second, this patient achieved HBsAg clearance after receiving bortezomib-based regimen combined with anti-HBV drug. To our knowledge, this is the first case report about HBsAg clearance following bortezomib-based regimen combined with entecavir as antiviral therapy.

Clearance of HBsAg is one of the important signs of HBV clearance. Possible causes of achieving HBsAg negativity include elimination of HBV and mutation of HBsAg antigen gene, due to which HBsAg is not expressed.[20] In this case, at the same time that the patient’s HBsAg turned negative, the HBV-DNA was also undetectable, which ruled out the possibility of HBsAg gene mutation leading to HBsAg clearance. Although the probability is low, spontaneous clearance of HBsAg still occurs in some HBsAg-positive patients.[21,22] However, this patient did not achieve spontaneous clearance of HBsAg in the past 20 years. Therefore, it is likely that this patient achieved HBsAg clearance by combined treatment with bortezomib and entecavir, rather than spontaneous clearance. However, some studies have shown that about 20% of the patients develop HBV reactivation 2 years after initiation of bortezomib treatment,[23] even in patients with resolved HBV infection.[1] Therefore, it remains to be seen whether HBV clearance will be maintained in this patient in the future.
HBsAg clearance is related to many factors, including HBV subtypes, treatment strategies, and certain genetic polymorphisms in patients. Therefore, low serum HBsAg levels in this patient might be a predictor for HBV clearance. Zhang et al. showed that bortezomib did not affect the replication of the wild-type HBV virus, while increasing the replication of X-negative HBV virus in vitro. This suggests that alterations in the HBV genome might also influence the effects of bortezomib on HBV. Patients of multiple myeloma patients are usually immunocompromised, which can also lead to reactivation of HBV. The multiple myeloma in our patient was probably initiated after initiating the PCD regimen and the improved immune status might also be one of the factors aiding the clearance of HBV. The effect of bortezomib on HBV is influenced by many factors; however, the detailed mechanism is still not understood.

Multiple myeloma is thought to have an inherent genetic component that might have existed about a century ago. Eight families with 2 or more first-degree relatives with multiple myeloma have been reported in 1974. Several systematic epidemiological family studies confirmed that first-degree relatives of patients with multiple myeloma have about 2 to 4 times higher risk of developing multiple myeloma. Recently, several Genome-Wide Association Studies (GWAS) studies have identified some DNA sequence variants at an independent locus that is associated with the risk of multiple myeloma. This patient and his elder brother were diagnosed with multiple myeloma at a similar age. Unfortunately, his brother died of multiple myeloma 3 years ago, and the exact genetic risk factors could not be determined. Our patient had a hereditary risk of multiple myeloma, and it is unclear whether some unknown genetic change could affect the outcome of his anti-HBV treatment. Whether there is a correlation between the genetic risk factors for multiple myeloma and the outcome of anti-HBV treatment needs further research.

Antiviral prophylaxis for HBV reactivation is recommended during the treatment of HBV patients with hematological malignancies, including multiple myeloma. Lu et al. showed that bortezomib combined with antiviral prophylaxis did not lead to HBV reactivation or abnormal liver functions. Therefore, it is safe to use prophylactic antiviral therapy in HBV positive patients with multiple myeloma who receive bortezomib-based therapy. Preventive antiviral treatment is feasible, both from the perspective of preventing HBV reactivation and in aiding clearance of the HBV infection. Clinical trials should be conducted in the future to verify whether bortezomib combined with anti-HBV drugs can clear HBV infection.

4. Conclusion

This case suggests that anti-HBV virus treatment while receiving bortezomib therapy might achieve clearance of HBV infection in some HBV-positive patients with multiple myeloma. However, this hypothesis needs further validation. Further research is necessary to understand the detailed mechanism. These mechanisms can bring a new hope for the treatment of HBV infection.

Acknowledgments

We thank Dr. Jinfan Li, from the Department of Pathology the Second Affiliated Hospital of Zhejiang University School of Medicine, for the kind help in pathology diagnosis and drafting the manuscript.

Author contributions

ZX and LY designed the study, ZX, LX, WW, TJ, and XY collected the data, ZX and XY wrote the manuscript. All authors have read and approved the final manuscript.

References

[1] Tsukune Y, Sasaki M, Odajima T, et al. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era. Ann Hematol 2016;95:1465–72.
[2] Lu J, Chen WM, Geng CY, et al. Efficacy and safety of bortezomib in multiple myeloma patients with hepatitis B: a multicenter retrospective study. Chin Med J (Engl) 2016;129:274–8.
[3] Wang C, Xia B, Ning Q, et al. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China. Ann Hematol 2018;97:453–7.
[4] Lalazar G, Rund D, Shoval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699–712.
[5] Ling WH, Soo PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumors. Br J Cancer 2013;108:1931–5.
[6] Mya DH, Han ST, Lim YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012;23:421–6.
[7] Belsey S, Yegin ZA, Yazici M. Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma. Turk J Gastroenterol 2010;21:197–8.
[8] Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematopatol 2012;5:67–9.
[9] Hussain S, Jhaj R, Ahsan S, et al. Bortezomib induced hepatitis B reactivation. Case Rep Med 2014;2014:964082.
[10] Goldberg R, Smith E, Bell S, et al. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B. Intern Med J 2013;43:835–6.
[11] Bandi P, Garcia ML, Booth CJ, et al. Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother 2010;54:749–56.
[12] Chan-an Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784–90.
[13] Huang B, Li J, Zhou Z, et al. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma 2012;53:270–4.
[14] Lamm KC, Lai CL, Trupo C, et al. Deletious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1983;304:380–6.
[15] Gu HR, Shin D-Y, Choi HS, et al. HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. Blood Res 2015;50:51–3.
[16] Li J, Huang B, Li Y, et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 2015;56:1710–7.
[17] Vama A, Brixtnaxa L, Saliba RM, et al. Impact of hepatitis B core antibody seropositivity on the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2017;23:581–7.
[18] Hou L, Zhao J, Gao S, et al. Restriction of hepatitis B virus replication by c-Ab1-induced proteasomal degradation of the viral polymerase. Sci Adv 2019;5:eaau7130.
[19] Wang Y, Li XL, Yu YS, et al. Inhibition of hepatitis B virus production in vitro by proteasome inhibitor MG132. Hepatogastroenterology 2013;60:837–41.
[20] Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007;132:543–50.
[21] Inverunzi F, Viganò M, Grossi G, et al. The prognosis and management of inactive HBV carriers. Liver Int 2016;36(suppl 1):100–4.
[22] Alawad AS, Auh S, Suarez D, et al. Durability of spontaneous and treatment-related loss of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2020;18:700–9.

[23] Tsukune Y, Sasaki M, Komatsu N. Reactivation of hepatitis B virus in patients with multiple myeloma. Cancer 2019;11:1819–36.

[24] Chihab H, Zaidane I, Elhabazi A, et al. Toll-like receptor 9 polymorphisms and hepatitis B virus clearance in Moroccan chronic carriers. Gene 2019;687:212–8.

[25] Khanizadeh S, Hasanvand B, Nikoo HR, et al. Association between miRNA-146a rs2910164 (G/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population. J Med Virol 2019;91:1063–8.

[26] Shoraka S, Mohbibi SR, Hosseini SM, et al. Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microb Pathog 2019;128:263–7.

[27] Rybicka M, Wozowicka A, Romanowski J, et al. Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B. J Clin Virol 2019;120:1–5.

[28] Wang H, Luo H, Wan X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol 2020;72:45–56.

[29] Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872–80.

[30] Zhang Z, Protzer U, Hu Z, et al. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol 2004;78:4566–72.

[31] Smalls DJ, Kiger RE, Norris LB, et al. Hepatitis B virus reactivation: risk factors and current management strategies. Pharmacotherapy 2019;39:1190–203.

[32] Maldonado JE, Kyle RA. Familial myeloma. Report of eight families and a study of serum proteins in their relatives. Am J Med 1974;57:875–84.

[33] Altieri A, Chen B, Bermejo JL, et al. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006;42:1661–70.

[34] Camp NJ, Werner TL, Cannon-Albright L. Familial myeloma. N Engl J Med 2008;359:1734–3.

[35] Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2012;44:58–61.

[36] Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013;45:1221–5.

[37] Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 2016;7:12050.